Recruiting studies: Beta Thalassemia Major Anemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
Phase N/A · 6 location(s) · Genetix Biotherapeutics Inc. · NCT06271512 Effect of Incentive Respiratory Training on Pulmonary Functions and Functional Capacity in Children With B-thalassemia M
NA · 1 location(s) · Rawan Mohammed Khairy Mostafa Elsawy · NCT07112703 AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 · 1 location(s) · Mitchell Cairo · NCT04099966 A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
EARLY_Phase 1 · 1 location(s) · First Affiliated Hospital of Guangxi Medical University · NCT05762510 Long-term Follow-up Study of BRL-101 for TDT
Phase N/A · 7 location(s) · Bioray Laboratories · NCT06298630 FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
Phase N/A · 1 location(s) · xCures · NCT06539169 RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
Phase N/A · 1 location(s) · Hospital Universitari Vall d'Hebron Research Institute · NCT06213402 Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
Phase 2 · 4 location(s) · New York Medical College · NCT02675959 Study of the Role of Genetic Modifiers in Hemoglobinopathies
Phase N/A · 26 location(s) · Cyprus Institute of Neurology and Genetics · NCT05799118 A Long-term Follow-up Study in Participants Who Received CS-101
NA · 1 location(s) · Children's Hospital of Fudan University · NCT06479616 A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
Phase 1 · 2 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06772766 Transfusion-Related Changes in Oxidative Stress Biomarkers in Neonates
Phase N/A · 1 location(s) · Medical University of Graz · NCT07672275 A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or
Phase N/A · 2 location(s) · Bristol-Myers Squibb · NCT06073860 Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Phase 2 · 26 location(s) · Celgene · NCT04143724 A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Tria
Phase 3 · 143 location(s) · Celgene · NCT04064060 Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia
Phase 2 · 1 location(s) · National Institute of Blood and Marrow Transplant (NIBMT), P · NCT06490627 Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT03937817 Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemia
NA · 2 location(s) · Guangzhou Women and Children's Medical Center · NCT06734520 Adherence of Beta Thalssemia Patients to Oral Chelation Therapy
NA · 1 location(s) · Sohag University · NCT06568926 Atrial Fibrillation in Beta-Thalassemia
Phase N/A · 1 location(s) · University Hospital of Ferrara · NCT05508932 A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an
Phase 2 · 6 location(s) · Memorial Sloan Kettering Cancer Center · NCT05736419 MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05735717 Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
Phase N/A · 1 location(s) · Paul Szabolcs · NCT04528355 International Registry of Patients With Alpha Thalassemia
Phase N/A · 1 location(s) · University of California, San Francisco · NCT04872179 Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06219239 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Di
Phase 1 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT05904093 T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
Phase 1/Phase 2 · 1 location(s) · Paul Szabolcs · NCT03653338 An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
NA · 1 location(s) · Ann & Robert H Lurie Children's Hospital of Chicago · NCT04688411 Long-term Follow-up Study of BHC001 for TDT
Phase N/A · 2 location(s) · Bioray Laboratories · NCT06314529 Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Phase 1/Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT07599176

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.